However, a further study highlighted the favorable effect of inhibiting JMJD3 in limiting tumor progression in vitro and in vivo with a decrease in cell proliferation and pluripotency markers (Nanog, Sox2, and Oct4) and in tumor size and weight after GSK-J4 treatment [90]. This evidence concerns the gene POU5F1 and neoplasm.